Price ($)
Liquidity ($)
Market Cap ($)
TXNS
Buys
LOADING...Sells
LOADING...Volume
"Yo, it's time for $WAT to show everyone how great you are on BSC chain! 🐹🔥 "
$WAT TO MERGE WITH $BDX IN $17.5B DEAL Waters and BD are combining BD’s Biosciences & Diagnostic Solutions unit with Waters in a $17.5B Reverse Morris Trust deal. BD shareholders will get 39.2% of the new company, while Waters shareholders keep 60.8%. BD also takes home a $4B cash payout before close. The merged business is expected to pull in $6.5B in 2025 revenue and $2B in adjusted EBITDA. Waters says it’ll double its addressable market to $40B and see $345M in synergies by 2030. The deal is set to close by Q1 2026.
$WAT Waters and BD's $BDX Biosciences & Diagnostic Solutions Business to Combine in ~$17.5B Deal, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing (Waters Corporation) (More at
🚨 Waters $WAT to acquire BD’s $BDX Biosciences & Diagnostic Solutions unit in a $17.5B Reverse Morris Trust spinoff + merger, creating a life sciences and diagnostics leader with ~$6.5B in pro forma 2025 revenue. 🔄 Deal Overview: BD will spin off the unit to its shareholders, who will then own 39.2% of the combined company. Waters shareholders will own 60.8%. 💰 Financial Synergies: Waters expects to generate $345M in annual EBITDA synergies by 2030—driven by $200M in cost savings and $290M in new revenue. 📈 Long-Term Outlook: By 2030, the combined company is expected to hit $9B in revenue, $3.3B in EBITDA, and a 32% adjusted operating margin. 📍Leadership & Structure: Post-close, Waters CEO Udit Batra will lead the combined company. It will retain the Waters name and NYSE:WAT ticker, headquartered in Milford, MA 💵 BD’s Payout & Timeline: BD receives a $4B cash distribution and plans to use proceeds for share buybacks and debt reduction. The deal is expected to close by Q1 2026, pending regulatory and shareholder approvals.
I've posted on Waters in the past... but this transaction, I dunno $WAT
$WAT -11.7%, $BDX flat [Becton Dickinson is spinning off its biosciences and diagnostic business to merge with Waters Corp for approximately $17.5B. BD will receive $4B in cash, with plans to use at least half for share repurchases. BD's stock has significantly declined since the initial separation announcement, partly due to government policy changes.]
$WAT + $BDX Bio/Diag merger in $17.5B RMT deal • Doubles TAM to $40B w/5-7% annual growth • Pro forma '25: $6.5B rev, $2B adj EBITDA • $345M EBITDA synergies by '30 • >70% recurring rev post-merger PR:
Imagine buying $WAT after the next 2x. That’s what you’re risking.
#DailyMovers: Value & Velocity July 14, 2025 📈 TOP GAINERS * $MCRB * $NBIS * $SMR * $OKLO * $TMC 📉 TOP LOSERS * $NEGG * $WAT * $CIVI * $RGEN * $GAP
Every second you wait, someone else presses market buy. $WAT 💚
$WAT to merge w/ BD Bio & Diag unit in $17.5B Reverse Morris Trust deal • Doubles $WAT TAM to ~$40B • Combined rev exp $6.5B & adj EBITDA $2B in '25 • $345M EBITDA synergies by '30 • >70% recurring rev post-merger PR:
$WAT - Waters Corporation will merge with Becton, Dickinson & Company's Biosciences and Diagnostics Solutions, forming a life sciences and diagnostics giant. Read more on
$WAT Really solid piece that nails WAT's current situation. So if you want to refresh your understanding of WAT or just get to know WAT, this is a must read.
If you’re still waiting for confirmation—you’ve already missed it. $WAT is then gone! 🤜🤛
Bearish momentum: $WAT faces high volatility and trend ambiguity. 📈 : 311.555$ 🔻-41.36 (-11.72%) More info, technical analysis and next targets: $SPX $DJI $QQQ #Waters #WAT #Investing #Stocks #Trading
💹 #trending in #stocks 1. $TLRY 2. $WAT 3. $MU 4. $APP 5. $IBG 📈 #trndboard
